Please use this identifier to cite or link to this item:
Title: Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate
Authors: Chan, Y.-H.
Teo, T.-H.
Utt, A.
Tan, J.J.L.
Amrun, S.N.
Abu Bakar, F.
Yee, W.-X.
Becht, E.
Lee, C.Y.-P.
Lee, B.
Rajarethinam, R.
Newell, E.
Merits, A.
Carissimo, G.
Lum, F.-M.
Ng, L.F.P. 
Keywords: chikungunya
live-attenuated vaccine
neutralizing antibody
non-structural protein
Issue Date: 2019
Publisher: Blackwell Publishing Ltd
Citation: Chan, Y.-H., Teo, T.-H., Utt, A., Tan, J.J.L., Amrun, S.N., Abu Bakar, F., Yee, W.-X., Becht, E., Lee, C.Y.-P., Lee, B., Rajarethinam, R., Newell, E., Merits, A., Carissimo, G., Lum, F.-M., Ng, L.F.P. (2019). Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate. EMBO Molecular Medicine 11 (6) : e10092. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Currently, there are no commercially available live-attenuated vaccines against chikungunya virus (CHIKV). Here, CHIKVs with mutations in non-structural proteins (nsPs) were investigated for their suitability as attenuated CHIKV vaccines. R532H mutation in nsP1 caused reduced infectivity in mouse tail fibroblasts but an enhanced type-I IFN response compared to WT-CHIKV. Adult mice infected with this nsP-mutant exhibited a mild joint phenotype with low-level viremia that rapidly cleared. Mechanistically, ingenuity pathway analyses revealed a tilt in the anti-inflammatory IL-10 versus pro-inflammatory IL-1? and IL-18 balance during CHIKV nsP-mutant infection that modified acute antiviral and cell signaling canonical pathways. Challenging CHIKV nsP-mutant-infected mice with WT-CHIKV or the closely related O'nyong-nyong virus resulted in no detectable viremia, observable joint inflammation, or damage. Challenged mice showed high antibody titers with efficient neutralizing capacity, indicative of immunological memory. Manipulating molecular processes that govern CHIKV replication could lead to plausible vaccine candidates against alphavirus infection. © 2019 Agency for Science, Technology and Research (A*STAR). Published under the terms of the CC BY 4.0 license
Source Title: EMBO Molecular Medicine
ISSN: 1757-4676
DOI: 10.15252/emmm.201810092
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_15252_emmm_201810092.pdf3.52 MBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons